Pulmonary hypertension

JAMA

Volumn 284, Issue 24, 2000, Pages 3160-3168

  Gaine, Sean ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN DERIVATIVE;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CASE REPORT; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DISEASE CLASSIFICATION; FEMALE; HEART CATHETERIZATION; HUMAN; HYPOXEMIA; LIVER DISEASE; LONG TERM CARE; MUSCLE HYPERTROPHY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY SYSTEM; THROMBOSIS;

EID: 0034722976     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.24.3160     Document Type: Article

References (49)

1. Primary pulmonary hypertension: A national prospective study
2. Approach to the patient with pulmonary hypertension
3. Primary pulmonary hypertension
4. The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion
5. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor. II gene
6. Heterozygous germline mutations in BMPR-II are the cause of familial primary pulmonary hypertension
7. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
8. Aminorex and pulmonary hypertension
9. Drug-induced pulmonary hypertension?
10. Aminorex and the pulmonary circulation
11. Long-term follow-up of pulmonary hypertension patients with and without anoretic drug intake
12. Oral contraceptives and progressive pulmonary vascular disease
13. Pulmonary hypertension in patients using oral contraceptives
14. Primary pulmonary hypertension
15. Primary pulmonary hypertension: ACCP consensus statement
16. Clinical, biochemical, electrocardiographic, and noninvasive hemodynamic assessment of cardiovascular status in natives at high to extreme altitudes (3000 m-5000 m) of the Himalaya region
17. Pulmonary "capillary" wedge pressure not the pressure in the pulmonary capillaries
18. Thromboendarterectomy for chronic, major vessel thromboembolic pulmonary hypertension: Immediate and long term results in 42 patients
19. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome
20. AIDS and primary pulmonary hypertension
21. Primary pulmonary hypertension in HIV infection
22. Distinctive clinical features of portopulmonary hypertension
23. Pulmonary hypertension - Beyond vasodilator therapy
24. Primary vascular pulmonary hypertension: Report on 21 patients
25. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
26. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
27. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
28. + channel gene transcription in primary pulmonary hypertension
29. +channels in human pulmonary artery smooth-muscle cells
30. Obesity, dexfenfluramine and pulmonary hypertension, a lesson not learned?
31. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
32. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
33. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: A dose-response study and comparison with prostacylin
34. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
35. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
36. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of diseases: A randomized, controlled study
37. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation
38. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension
39. Primary pulmonary hypertension: Natural history and the importance of thrombosis
40. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
41. Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension
42. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth official report, 1997
43. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension
44. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostaglandin analogue
45. Acute hemodynamic effects of subcutaneous UT-15 in primary pulmonary hypertension
46. Hemodynamic effects of bosentan, an enothelin receptor antagonist, in patients with pulmonary hypertension